Barclays
ONCT

Barclays’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Barclays’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-181
Closed -$4K – 5235
2022
Q2 		$4K Sell
181
-360
-67% -$8.03K ﹤0.01% 4829
2022
Q1 		$15K Sell
541
-2,326
-81% -$84.7K ﹤0.01% 4521
2021
Q4 		$130K Buy
2,867
+1,781
+164% +$120K ﹤0.01% 3679
2021
Q3 		$91K Sell
1,086
-1,309
-55% -$108K ﹤0.01% 3942
2021
Q2 		$228K Buy
+2,395
New +$284K ﹤0.01% 3488
2019
Q4 		– Sell
-1
Closed – – 6944
2019
Q3 		$0 Sell
1
-47
-98% -$4.81K ﹤0.01% 7247
2019
Q2 		$6K Buy
48
+22
+85% +$3.4K ﹤0.01% 6667
2019
Q1 		$5K Sell
26
-29
-53% -$4.33K ﹤0.01% 6726
2018
Q4 		$7K Buy
55
+36
+189% +$7.2K ﹤0.01% 6349
2018
Q3 		$4K Sell
19
-12
-39% -$28.8K ﹤0.01% 6849
2018
Q2 		$66K Sell
31
-15
-33% -$38K ﹤0.01% 5493
2018
Q1 		$115K Sell
46
-10
-18% -$22.3K ﹤0.01% 5283
2017
Q4 		$100K Buy
+56
New +$81.1K ﹤0.01% 5242
2017
Q3 		– Hold
0
– – – 7108
2017
Q2 		– Hold
0
– – – 7016
2017
Q1 		– Hold
0
– – – 7051
2016
Q4 		– Hold
0
– – – 6901
2016
Q3 		– Hold
0
– – – 6854
2016
Q2 		– Hold
0
– – – 6710
2014
Q3 		– Hold
0
– – – 7867
2014
Q2 		– Sell
-1
Closed -$1.98K – 7851
2014
Q1 		$2K Sell
1
-10
-91% -$24.9K ﹤0.01% 7415
2013
Q4 		$16K Sell
11
-20
-65% -$45.7K ﹤0.01% 6827
2013
Q3 		$86K Sell
31
-23
-43% -$114K ﹤0.01% 5741
2013
Q2 		$496K Buy
+54
New +$416K ﹤0.01% 4206

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's ONCT Position: Q3 2022 in Review

Barclays sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 181 shares — an estimated $4K sold.

Barclays first reported a position in ONCT in Q2 2013 and held it in 17 quarters. The position peaked at $496K in Q2 2013. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Barclays reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 181 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Barclays first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
  • Barclays's Oncternal Therapeutics, Inc. Common Stock position peaked at $496K in Q2 2013.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.